Bệnh gan nhiễm mỡ không do rượu, một bệnh lý gan có liên quan đến nội tiết

Marchesini G, Day CP, Dufour JF et al. (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388–1402 Cusi K, Sanyal AJ, Zhang S et al. (2017) Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab 19:1630–1634 Targher G, Mantovani A, Byrne CD et al. (2020) Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut 69(8):1545–1547 Bellanti F, Villani R, Facciorusso A et al. (2017) Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radic Biol Med 111:173–185 Lonardo A, Ballestri S, Marchesini G et al. (2015) Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47(3):181–190 Dowman J, Tomlinson J, Newsome P (2010) Pathogenesis of non-alcoholic fatty liver disease. Q J Med 103:71–83 Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8):1038–1048 Eslam M, Sanyal AJ, George J et al. (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999–2014 Sivamaruthi BS, Kesika P, Suganthy N et al. (2019) A review on role of microbiome in obesity and antiobesity properties of probiotic supplements. Hindawi BioMed Res Int 2019:3291367 Kirpich IA, Marsano LS, McClain CJ (2015) Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 48:923–930 Lonardo A, Carani C, Carulli N et al. (2006) ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol 44:1196–1207 Lonardo A, Mantovani A, Lugari S et al. (2019) NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci 20(11):2841 Rockall AG, Sohaib SA, Evans D et al. (2003) Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 149:543–548 Targher G, Bertolini L, Rodella S et al. (2006) Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol 64:337–341 Stanley TL, Fourman LT, Zheng I et al. (2021) Relationship of IGF-1 and IGF binding proteins to disease severity and glycemia in non-alcoholic fatty liver disease. J Clin Endocrinol Metab 106(2):e520–e533 Gardner CJ, Irwin AJ, Daousi C et al. (2012) Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol 166:993–1002 Poggiogalle E, Lubrano C, Gnessi L et al. (2016) Fatty liver index associates with relative sarcopenia and GH/IGF-1 status in obese subjects. PLoS ONE 11(1):1–9 Shao S, Yao Z, Lu J et al. (2018) Ablation of prolactin receptor increases hepatic triglyceride accumulation. Biochem Biophys Res Commun 498(3):693–699 Zhang P, Feng W, Chu X et al. (2019) A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 19(202):1–10 Jaruvongvanich V, Sanguankeo A, Riangwiwat T et al. (2017) Testosterone, sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Hepatol 16(3):382–394 Huang G, Bhasin S, Tang ER et al. (2013) Effect of testosterone administration on liver fat in older men with mobility limitation: results from a randomized controlled trial. J Gerontol 68(8):954–959 Rocha AL, Faria LC, Guimarães TC et al. (2017) Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest 40(12):1279–1288 Polyzos SA, Kountouras J, Tsatsoulis A et al. (2013) Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease. Hormones 12(3):405–416 Lonardo A, Nascimbeni F, Ballestri S et al. (2019) Sex differences in NAFLD: state of the art and identification of research gaps. Hepatology 70(4):1457–1469 Kizivat T, Maric I, Mudri D et al. (2020) Hypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications. J Clin Tranl Hepatol 8(3):347–353 Younossi ZM, Golabi P, de Avila L et al. (2019) The global epidemiology of NALFD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019(71):793–801 Hazlehurst JM, Woods C, Marjot T et al. (2016) Non-alcoholic fatty liver disease and diabetes. Metab Clin Exp 65:1096–1108 de Vries M, Westerink J, Kaasjager KH et al. (2020) Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. J Clin Endocrinol Metab 105(12):1–12 Targher G, Pichiri I, Zoppini G et al. (2012) Increased prevalence of cardiovascular disease in type 1 diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest 35:535–540